How policymakers value end-of-life treatments for rare and common diseases in China: evidence from a contingent valuation study
This study provides novel estimates of Chinese policymakers' WTP per QALY specifically in end-of-life contexts involving common and rare diseases, highlighting the significant impact of disease rarity on reimbursement decisions. These findings offer empirical support for adopting differentiated cost-effectiveness thresholds tailored to end-of-life treatments based on disease rarity in China.
Authors
- Haiyin Wang (ORCID: https://orcid.org/0000-0001-9560-0460)
- Shan Jiang (ORCID: https://orcid.org/0000-0003-1015-1278)
- Yuanyuan Gu (ORCID: https://orcid.org/0000-0002-3816-9106)
- Han Cheng (ORCID: https://orcid.org/0000-0001-5534-4140)
- Shanquan Chen (ORCID: https://orcid.org/0000-0002-4724-4892)
- Hao Chen (ORCID: https://orcid.org/0000-0003-1562-2200)
- Ao Li (ORCID: https://orcid.org/0000-0003-0735-2917)
- Boyang Li (ORCID: https://orcid.org/0000-0002-6230-2376)
Institutions
- City University of Hong Kong (HK)
- Sichuan University (CN)
- Wuhan University (CN)
- Shanghai Medical Information Center (CN)
- London School of Hygiene & Tropical Medicine (GB)
- Huazhong University of Science and Technology (CN)
- Macquarie University (AU)
Publication Details
- Journal
- Global Health Research and Policy
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1186/s41256-025-00434-w
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00